Divergent local and systemic antitumor response in primary uveal melanomas
Authors:
- Francesca LucibelloFLFrancesca Lucibello
- Ana I. LalanneALAna I. Lalanne
- Anne-Laure Le GacAGAnne-Laure Le Gac
- Abdoulaye SoumareASAbdoulaye Soumare
- Setareh AflakiSASetareh Aflaki
- Joanna CyrtaJCJoanna Cyrta
- Lea DubreuilLDLea Dubreuil
- Martin MestdaghMMMartin Mestdagh
- Marion SalouMSMarion Salou
- Alexandre HouyAHAlexandre Houy
- Christina EkwegbaraCEChristina Ekwegbara
- Camille JametCJCamille Jamet
Open Access
- 2 April 2024
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 221 (6)
Abstract
Uveal melanoma (UM) is the most common cancer of the eye. The loss of chromosome 3 (M3) is associated with a high risk of metastases. M3 tumors are more infiltrated by T-lymphocytes than low-risk disomic-3 (D3) tumors, contrasting with other tumor types in which T cell infiltration correlates with better prognosis. Whether these T cells represent an antitumor response and how these T cells would be primed in the eye are both unknown. Herein, we characterized the T cells infiltrating primary UMs. CD8+ and Treg cells were more abundant in M3 than in D3 tumors. CD39+PD-1+CD8+ T cells were enriched in M3 tumors, suggesting specific responses to tumor antigen (Ag) as confirmed using HLA-A2:Melan-A tetramers. scRNAseq-VDJ analysis of T cells evidenced high numbers of proliferating CD39+PD1+CD8+ clonal expansions, suggesting in situ antitumor Ag responses. TCRseq and tumor-Ag tetramer staining characterized the recirculation pattern of the antitumor responses in M3 and D3 tumors. Thus, tumor-Ag responses occur in localized UMs, raising the question of the priming mechanisms in the absence of known lymphatic drainage.Keywords
Funding Information
- Agence Nationale de la Recherche (ANR10EQPX03, ANR10INBS0908, ANR-10-IDEX-0001-02, LabEx DCBIOL)
- ITMO-Cancer Aviesann
- SiRIC-Curie (INCa-DGOS-465, INCa-DGOS-Inserm_12554)
- Institut National de la Santé et de la Recherche Médicale
- Institut Curie
- Ligue Contre le Cancer
- French Government
- Cancéropôle Ile-de-France
- European Union’s Horizon 2020 research and innovation (667787)
- SIRIC2 (INCa-DGOS-Inserm_12554)
This publication has 47 references indexed in Scilit:
- Determinants of overall survival in patients with metastatic uveal melanomaCancer, 2023
- Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapyCell, 2022
- Lymphatic vessels of the eye – old questions – new insightsAnnals of Anatomy - Anatomischer Anzeiger, 2019
- Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal MelanomaCancer Cell, 2017
- Uveal Melanomas with SF3B1 MutationsOphthalmology, 2016
- Structural and agonist properties of XCL2, the other member of the C-chemokine subfamilyCytokine, 2015
- Inflammation in uveal melanomaEye, 2012
- Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramersJournal of Immunological Methods, 2009
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature, 2008
- Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral InfectionImmunity, 2007